TY - JOUR T1 - CD40L-Transfected Myeloma Cells Transfer Prolonged Immunity <em>In Vivo</em> JF - In Vivo JO - In Vivo SP - 45 LP - 48 VL - 24 IS - 1 AU - YOUNG KIM AU - JOHN W. STREHL AU - ELISABETH SIEVERS AU - MARCUS GORSCHLÜTER AU - PETER BROSSART AU - INGO G.H. SCHMIDT-WOLF Y1 - 2010/01/01 UR - http://iv.iiarjournals.org/content/24/1/45.abstract N2 - Background: In a large number of patients with multiple myeloma, chemotherapy is the only therapeutic option. During recent years, major effort has been put into immunotherapeutic approaches for this malignancy. Materials and Methods: In this study, wild-type (wt) myeloma cells (5×105) were injected subcutaneously into Balb/c mice. CD40L-transfected myeloma cells (5×105) were subsequently injected intratumorally into the established (&gt;100 mm3) wt tumor nodules. Overall survival and tumor growth were measured. Results: Out of eight animals receiving wt tumor cells, one died prior to the formation of a solid tumor nodule. Following the CD40L-transfected myeloma cell injection, stable complete remission at day 60 with all the animals surviving resulted. On day 60, a re-challenge was performed with wt myeloma cells. No tumor growth was observed after 120 days out of seven remaining animals, one died. Conclusion: Intratumoral injection of CD40L-transfected myeloma cells induces complete tumor remission and long lasting immunity against tumor recurrence. Copyright © 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -